Group 1 - Orion Corporation has received a disclosure regarding transactions made by its board member Veli-Matti Mattila under Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 830 shares at a unit price of 0 EUR [1] - The aggregated transaction also reflects a volume of 830 shares with a volume weighted average price of 0 EUR [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Kari Jussi Aho, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation is a Nordic pharmaceutical company with a history of over a hundred years, focusing on human and veterinary pharmaceuticals, and has a diverse portfolio including proprietary and generic medicines [2] Group 2 - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member, Karen Lykke Sørensen, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - In 2024, Orion's net sales amounted to EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company, developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain in its pharmaceutical R&D [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Managerial Transactions - Eija Ronkainen, a member of the Board and Deputy member, made an initial notification regarding a transaction involving shares of Orion Corporation [1] - The transaction occurred on April 30, 2025, involving the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - The aggregated transaction also reported a volume of 415 shares with a volume-weighted average price of 0 EUR [1]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Ari Lehtoranta, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 508 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation's net sales for 2024 amounted to EUR 1,542 million, and the company employs approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company with a focus on developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, with core therapy areas in oncology and pain [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Core Insights - Orion Corporation has reported a transaction involving Hilpi Rautelin, a member of the Board, who received a share-based incentive on April 30, 2025 [1] - The transaction involved 508 shares with a unit price of 0 EUR, indicating a non-monetary incentive [1] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience in developing, manufacturing, and marketing pharmaceuticals and active pharmaceutical ingredients [2] - The company focuses on oncology and pain management in its pharmaceutical R&D, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's shares are listed on Nasdaq Helsinki, comprising both A and B shares [2]

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Maziar Mike Doustdar Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Maziar Mike D ...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader:Investec Bank plc(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeGlobalData plc(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint B ...

Municipality Finance PlcStock exchange release 2 May 2025 at 11:00 am (EEST) Municipality Finance issues a EUR 50 million tap under its MTN programme On 5 May 2025 Municipality Finance Plc issues a new tranche in an amount of EUR 50 million to an existing benchmark issued on 29 August 2024. With the new tranche, the aggregate nominal amount of the benchmark is EUR 1.150 billion. The maturity date of the benchmark is 29 August 2029. The benchmark bears interest at a fixed rate of 2.500 % per annum. The new ...

Core Viewpoint - The suspension of live trading for certain funds on Nasdaq Copenhagen has been lifted, allowing trading to resume on May 2 [1] Group 1: Fund Information - The following funds and their respective share classes will resume trading: SKAGEN Focus A, SKAGEN Global A, SKAGEN Kon-Tiki A, SKAGEN m2 A, SKAGEN Vekst A, Storebrand Indeks – Alle Markeder A5, Storebrand Indeks – Nye Markeder A5, Storebrand Global Plus A5, Storebrand Global Solutions A5, Storebrand Global Multifactor A5 [1] - Each fund is identified by its symbol and ISIN, ensuring clarity for investors [1] Group 2: Company Overview - Storebrand is Norway's largest private asset manager with assets under management (AuM) of approximately DKK 900 billion [1] - The company is a leading Nordic provider of sustainable pensions and savings, with over 30 years of experience in ESG investing [1] - Storebrand offers a multi-boutique platform in Denmark, delivering sustainable investment solutions through various brands including Storebrand Funds and SKAGEN Funds [1]